<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475444</article-id><article-id pub-id-type="pmcid-ver">PMC12475444.1</article-id><article-id pub-id-type="pmcaid">12475444</article-id><article-id pub-id-type="pmcaiid">12475444</article-id><article-id pub-id-type="pmid">41006545</article-id><article-id pub-id-type="doi">10.1038/s41598-025-17658-y</article-id><article-id pub-id-type="publisher-id">17658</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6907-1702</contrib-id><name name-style="western"><surname>Hwang</surname><given-names initials="H">Helen</given-names></name><address><email>helenhwang@wustl.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0096-1085</contrib-id><name name-style="western"><surname>Dhavale</surname><given-names initials="DD">Dhruva D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="SJ">Sarah J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guduputi</surname><given-names initials="A">Ajay</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beale</surname><given-names initials="JM">John M.</given-names><suffix>Jr.</suffix></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9858-3344</contrib-id><name name-style="western"><surname>Cairns</surname><given-names initials="NJ">Nigel J.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7155-114X</contrib-id><name name-style="western"><surname>Kotzbauer</surname><given-names initials="PT">Paul T.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01yc7t268</institution-id><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2355 7002</institution-id><institution>Department of Neurology and Hope Center for Neurological Disorders, </institution><institution>Washington University School of Medicine, </institution></institution-wrap>St. Louis, MO 63110 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01btzz102</institution-id><institution-id institution-id-type="GRID">grid.419579.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 8660 3507</institution-id><institution>St. Louis College of Pharmacy, </institution></institution-wrap>Saint Louis, MO 63110 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03yghzc09</institution-id><institution-id institution-id-type="GRID">grid.8391.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8024</institution-id><institution>Department of Clinical and Biomedical Sciences, </institution><institution>University of Exeter, </institution></institution-wrap>Exeter, EX4 4QD UK </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>33108</elocation-id><history><date date-type="received"><day>10</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_17658.pdf"/><abstract id="Abs1"><p id="Par1">Alpha-synuclein (asyn) fibril accumulation is the defining feature of Parkinson disease and is a target for disease-modifying treatments. One therapeutic strategy to reduce fibril accumulation is inhibition of asyn fibril growth. We developed a sensitive fluorescence-based fibril growth assay to screen for small molecule inhibitors. After validating the inhibition assay using a previously identified inhibitor, epigallocatechin-3-gallate, we identified compound <bold>1</bold> as a lead for inhibition of fibril growth. We analysed structure-activity relationships with analogs of <bold>1</bold> to optimize inhibition potency. Our results identified two dimethoxyphenyl piperazine analogs with more potent inhibition of in-vitro assembled fibrils, which were further validated with orthogonal assays including kinetic measurements of fibril concentration with Thioflavin T. These analogs also inhibited the growth of asyn fibrils amplified from Lewy Body Disease brain tissue, further validating the inhibitor screening assay. Molecular docking studies indicate that these compounds can bind to the fibril ends, suggesting a potential capping mechanism through which these compounds inhibit the sequential association of monomeric asyn required for fibril growth.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-17658-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alpha-synuclein fibril</kwd><kwd>Fibril growth inhibition</kwd><kwd>Parkinson&#8217;s disease</kwd><kwd>Small molecule inhibitors</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Parkinson's disease</kwd><kwd>Drug discovery and development</kwd></kwd-group><funding-group><award-group><funding-source><institution>American Parkinson Disease Association</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>American Academy of Neurology Clinical Research Training Scholarship in Parkinson&#8217;s Disease</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Michael J. Fox Foundation</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>NIH grants NS110436, NS097799, NS075321</award-id><principal-award-recipient><name name-style="western"><surname>Kotzbauer</surname><given-names>Paul T.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Alpha-synuclein (asyn) is a small 140 amino acid protein that regulates synaptic vesicle-mediated protein trafficking<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In its native form, asyn is a disordered soluble monomeric protein. The N-terminus forms an amphipathic alpha-helix upon interactions with membranes. In the formation of fibrils, asyn adopts a fibrillar cross-beta sheet structure, which is considered pathologic<sup><xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR4">4</xref></sup>. Misfolding of asyn into beta-sheet amyloid fibrils coupled with accumulation is linked to the pathophysiology of Parkinson&#8217;s disease (PD) and Lewy body dementia (LBD), the dementia associated with PD<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Furthermore, dominantly inherited mutations in the gene encoding asyn (SNCA) have been identified in rare forms of hereditary parkinsonism that are also characterized by asyn fibril accumulation, supporting asyn fibril accumulation as a therapeutic target<sup><xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par3">Asyn fibril accumulation involves an initial nucleation event, where two or more asyn monomers come together to form a misfolded oligomeric seed or protofibril. Nucleation is followed by the growth phase or elongation phase, where the sequential addition of asyn monomers leads to the formation of fibrils with beta-sheet structure. Previous studies have utilized several approaches to identify inhibitors for asyn fibril nucleation and growth<sup><xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref></sup>. Stabilizing the monomeric form of asyn by DNA aptamers &#207;formation<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Others have shown that some polyphenols, including (&#8722;)-epigallocatechin gallate (EGCG) can redirect monomeric asyn to form off-pathway spherical oligomers and thus inhibit beta-sheet fibril formation<sup><xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref></sup>. Dopamine and other catecholamines can similarly promote the formation of non-fibrillar oligomeric forms of asyn<sup><xref ref-type="bibr" rid="CR27">27</xref>&#8211;<xref ref-type="bibr" rid="CR30">30</xref></sup>. Other molecules, such as select antibiotics<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,</sup>pigments<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref>,</sup>glucosides<sup><xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR37">37</xref>,</sup>quinones<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,</sup>and pirimido-pyrazine<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup> also have the potential to inhibit asyn aggregation.</p><p id="Par4">Conventional in vitro screening approaches to identify inhibitors of asyn fibril accumulation commonly utilize a non-seeded aggregation approach<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. One study adopted a seed amplification approach with repeated incubation and sonication to achieve exponential growth<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Both types of studies typically use high monomeric asyn concentrations (25-140 &#181;M), continuous orbital rotation, and lengthy incubation time (16&#8211;48&#160;hours)<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. We hypothesize that isolating and targeting the fibril growth pathway may yield additional candidate inhibitors for drug discovery.</p><p id="Par5">Asyn fibril accumulation is typically quantified by measuring Thioflavin T (ThioT) fluorescence, either continuously or at an endpoint after a 24&#8211;36 hour incubation period. ThioT is a fluorescent dye that is weakly fluorescent in the presence of monomeric asyn but undergoes a substantial increase in fluorescence intensity by several orders of magnitude upon binding to amyloid fibrils, including the beta sheets of asyn fibrils. We previously developed a fluorescence-based fibril growth assay that uses fluorescein arsenical hairpin binder (FlAsH) to detect the association of two or more asyn monomers with bicysteine tags<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. The FlAsH assay relies on quiescent incubation of monomeric asyn with a bicysteine (C2) tag and wildtype asyn fibril seeds without C2 tag and can be used to study linear rates of fibril growth when either soluble oligomers or sonicated fibril seeds are combined with monomeric asyn. Furthermore, the incubation time is short (3 hours), during which the rate of fibril growth is constant. Since wild-type (WT) asyn fibril seeds produce no FLASH fluorescence, the fluorescence signal is specific to fibril elongation with C2-asyn. We previously observed similar growth kinetics with C2-asyn monomer and WT-asyn monomer, using ThioT as a readout, suggesting that addition of a bicysteine tag on the N terminus of asyn does not interfere with fibril growth. Previous experiments comparing ThioT and FlAsH show that assays utilizing FlAsH fluorescence measurements have a 4 to 60-fold higher Z&#8217;-factor, a measure of the dynamic range and separation between signal and controls, as well as a 10-fold increase in signal/background ratio compared to ThioT<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Given the higher sensitivity of FlAsH dye compared to ThioT fluorescence, this approach is able to detect small changes in fibril growth over shorter periods of time (3&#160;hours)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>providing several advantages as a screening assay.</p><p id="Par6">We further developed the FlAsH fibril growth assay to screen small molecule compounds by using lower concentrations of monomer and fibril seeds and a short incubation period. We validated that this fibril growth assay measures an inhibitory effect of EGCG on fibril growth as observed in previous studies with ThioT and then used this fibril growth assay to identify lead compound <bold>1</bold>. To identify more potent inhibitors, we performed a series of structure-activity testing and identified two analogs of <bold>1</bold> that were more potent inhibitors. These analogs of <bold>1</bold> also inhibited the growth of asyn fibrils amplified from postmortem Lewy Body disease (LBD) brain tissue.</p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>An in vitro Asyn fibril growth assay for screening small molecule inhibitors</title><p id="Par7">Inhibition of fibril growth by small molecule compounds is likely to be mediated primarily by binding interactions with either monomer, fibrils, or both. However, secondary nucleation may occur and contribute to fibril growth under some conditions, and compounds may affect growth through interaction with oligomeric intermediates to inhibit conversion to fibrils. In one proposed mechanism, a compound binds to the end surface of fibrils and interferes with the binding of the new monomer required to extend the seed or fibril (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>)<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. Since binding will deplete the free concentration of the inhibitor, measured IC<sub>50</sub> values will be proportional to the concentration of the binding target (fibril seeds) and proportional to the concentration of monomer, with which the inhibitor competes for binding. We previously observed linear increases in fibril concentration when we varied the incubation time and observed a linear increase in FlAsH fluorescence<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Thus, we sought to optimize the FlAsH fibril growth assay by decreasing the concentrations of monomer and fibril seeds and found that a combination of 1 &#181;M fibril seeds, 3 &#181;M monomer, and 3-hour incubation time provided sufficient signal to analyze dose-response curves and determine IC<sub>50</sub> values. Under these assay conditions, we observed linear relationships between asyn fibril concentration and FlAsH fluorescence and between asyn monomer concentration and FlAsH fluorescence (Supplementary Fig. <xref rid="Fig1" ref-type="fig">1</xref>A and 1B). The increase in FlAsH fluorescence intensity was Linear between 3 and 6&#160;hours (Supplementary Fig. <xref rid="Fig1" ref-type="fig">1</xref>C), indicating sufficient monomer concentration to maintain a constant growth rate over this time period, but the rate of increase declined beyond 6&#160;hours (data not shown). These results support the hypothesis that the assay primarily measures the rate of fibril elongation under these conditions, although we have not directly observed the elongation process.</p><p id="Par8">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Schematic of fibril growth inhibition. Proposed mechanism of inhibition of asyn fibril growth by a small molecule inhibitor (pink) binding to the end surface of fibrils.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e412" position="float" orientation="portrait" xlink:href="41598_2025_17658_Fig1_HTML.jpg"/></fig>
</p><p id="Par9">We utilized the optimized FlAsH assay to evaluate a previously identified fibril growth inhibitor, EGCG, and observed dose-dependent inhibition with an inhibition constant (IC<sub>50</sub>) of 8&#8201;&#177;&#8201;1 &#181;M (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). Interestingly, control reactions containing EGCG with no seeds showed increased fluorescence signal at high EGCG concentrations. This may correspond to the formation of off-pathway oligomers previously observed when asyn is incubated with EGCG<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. We then tested a compound we previously identified as a potential Ligand for asyn in molecular docking studies, ethyl 1-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]piperidine-4- carboxylate (<bold>1</bold>), and observed that <bold>1</bold> inhibits fibril growth with an IC<sub>50</sub> of 18 &#181;M (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B and C). In contrast to EGCG, the fluorescence signal did not increase in the control reactions of <bold>1</bold> with no added fibril seeds (monomer only), indicating the absence of oligomer formation or spontaneous nucleation of fibrils over the 3-hour incubation period.</p><p id="Par10">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Inhibition of fibril growth by EGCG and newly identified compounds. (<bold>A</bold>) Representative dose-response curve for EGCG in an optimized fibril growth assay based on FlAsH fluorescence. Note the increased fluorescence signal for monomer plus EGCG at 30 &#181;M concentration, limiting the measurement of fibrils at this concentration. (<bold>B</bold>) Representative dose-response for <bold>1</bold> in the optimized fibril growth assay. The fluorescence signal is low in the presence of monomer only and does not increase significantly with increasing compound concentrations. (<bold>C</bold>) Chemical structure of <bold>1</bold> with shaded areas indicating regions where modifications were tested for structure-activity relationship (SAR) studies. (<bold>D</bold>) Chemical structure of <bold>10</bold> with shading that indicates the region that was modified for the third set of structure-activity relationship studies. (<bold>E</bold>) Representative dose-response for <bold>10</bold> in the optimized fibril growth assay. The fluorescence signal is low in the presence of monomer only and does not increase significantly with increasing compound concentrations. Data points represent mean&#8201;&#177;&#8201;standard deviation (std) (triplicates; <italic toggle="yes">n</italic>&#8201;=&#8201;3 independent experiments).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e483" position="float" orientation="portrait" xlink:href="41598_2025_17658_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>Screening additional analogs identifies structure-activity relationships for fibril growth inhibitors</title><p id="Par11">To determine whether we can further improve the inhibition potency of compound <bold>1</bold>, we examined 29 analogs of <bold>1</bold> in three rounds of structure-activity relationship (SAR) analysis. First, we examined several analogs (<bold>2&#8211;4</bold>) with alternate substitutions in the benzyl group on the left-hand side of <bold>1</bold> (Supplementary Fig. <xref rid="Fig2" ref-type="fig">2</xref>&#8201;A, SAR1). We observed a loss of inhibition potency for all of these analogs. Next, when the piperidine in <bold>1</bold> was replaced with a piperazine and the ester was replaced with a chlorobenzyl-piperazinyl (<bold>5</bold>), the inhibition improved to 15 &#181;M, and max inhibition was 99% compared to 18 &#181;M and 79%, respectively, for <bold>1</bold>. Other substitutions of <bold>1</bold> with another piperazinyl or piperidine (<bold>6 and 7</bold>) did not improve fibril growth inhibition (right side, SAR2, Supplementary Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). We subsequently screened 23 piperazine analogs (<bold>8&#8211;30</bold>) with modification on the right-hand side and found several dimethoxyphenol piperazine compounds (<bold>8&#8211;13</bold>) that were more potent (lower IC<sub>50</sub>) and had greater maximum inhibition than <bold>1</bold> (Table&#160;1). For example, <bold>10</bold>, a piperazinyl dimethoxylphenol ethanedioate, had an IC<sub>50</sub> of 9&#8201;&#177;&#8201;3 &#181;M (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>D and E). The analogs of <bold>1</bold> can be further divided into classes of phenacyl (<bold>8</bold>), pyridinyl (<bold>9</bold>), dimethoxy benzyl (<bold>10</bold>, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>D), methoxy benzyls (<bold>11</bold> and <bold>13</bold>), and halogen benzyls (<bold>5</bold> and <bold>12</bold>). Substitutions that included bulkier subgroups (<bold>14</bold>,<bold> 15</bold>,<bold> 18</bold>,<bold> 19</bold>,<bold> 20</bold>,<bold> and 21</bold>) and thiol-containing analogs (<bold>28</bold>,<bold> 29</bold>, and <bold>30</bold>) had little inhibitory effect (Supplementary Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). We also confirmed that 100 &#181;M solutions of the test compounds had less than 15% higher native fluorescence relative to buffer alone, at the FlAsH excitation/emission wavelengths (Supplementary Table 1). We further evaluated whether apparent inhibitory effects were due to the fluorescence quenching of the FlAsH dye by the test compounds (Supplementary Table 2). Only two of the compounds (<bold>6</bold> and <bold>15</bold>) had quenching of more than 25% fluorescence in the presence of fibrils pre-assembled in vitro with C2-asyn monomers and incubated with FlAsH, but these two compounds showed minimal inhibition of fibril growth (Supplementary Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B and Supplementary Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). This further confirmed that the inhibitory effects observed for the compounds were not due to quenching of FlAsH dye by the compounds at higher concentrations.</p><p id="Par12">We observed no change in FlAsH fluorescence after C2-asyn fibrils were incubated with the compounds in the absence of monomer for 3&#160;hours, suggesting that these compounds do not disrupt or disaggregate the fibrils (Supplementary Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). We further examined fibril growth products of our lead compounds <bold>8</bold> and <bold>10</bold> after growth with negative stain transmission electron microscopy (TEM). We observed similar asyn fibril morphology in the absence and presence of our two lead compounds (Supplementary Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). Given the variable asyn fibril density captured on grid, we were unable to quantify fibril concentration differences.</p><p id="Par13">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Compounds with highest Inhibition potency after 3 rounds of structure-activity screening</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e638" orientation="portrait" xlink:href="41598_2025_17658_Tab1_HTML.jpg"/><table-wrap-foot><p>The structures share a piperazinyl and a 4-hydroxy-3,5-dimethoxybenzylgroups. IC<sub>50</sub> is the mean&#8201;&#177;&#8201;standard deviation (std) and maximum inhibition is calculated as a (Intensity<sub>100&#181;M</sub>-Intensity<sub>0&#181;M</sub>)/intensity<sub>0&#181;M</sub> from three independent experiments.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec5"><title>Fibril growth inhibition confirmed by conformation-specific immunoassay</title><p id="Par14">To confirm the inhibition of fibril growth for compounds <bold>8</bold> and <bold>10</bold>, we used an orthogonal fibril growth assay that does not rely on fluorescence. We developed a sandwich enzyme-linked immunosorbent assay (ELISA) that utilizes a conformation-specific antibody (Abcam 209538, MJFR-14-6-4-2)<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> in the capture step and an in-house monoclonal antibody 13G5 <sup>48</sup> to measure fibril concentration at the end of the growth assays. This immunoassay is approximately 300-fold more sensitive for detecting fibrils than monomers (Supplementary Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). In contrast to the FlAsH assay, this immunoassay measures the level of fibril seeds at baseline, and growth is measured as an increase in signal relative to the baseline signal of fibril seeds. We increased the incubation time for the fibril growth reaction to 20&#160;hours and increased the asyn monomer concentration to 6 &#181;M, in order to increase the amount of fibril growth and compensate for the reduced sensitivity of the immunoassay relative to the FlAsH assay. Under these conditions, fibril concentrations increase by 70&#8211;100% over 20&#160;hours in the absence of inhibitor compounds. We confirmed that the presence of the compound decreased fibril growth as measured by the ELISA in a concentration-dependent manner for compounds <bold>8 and 10</bold> (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). FlAsH fluorescence measurements in parallel reactions showed similar inhibition patterns. (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B). It is possible that during these extended incubation times, the ELISA may be measuring a combination of molecular events that increase fibril concentration, including elongation as well as primary or secondary nucleation. However, in this context, the orthogonal assay provides confirmation that compounds <bold>8</bold> and <bold>10</bold> inhibit fibril accumulation and that the FlAsH assay can successfully identify inhibitory compounds.</p><p id="Par15">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>An immunoassay specific for asyn fibrils confirms that compounds inhibit fibril growth. (<bold>A</bold>) Dose-response curves for <bold>8</bold> (top) and <bold>10</bold> (bottom) using a conformational-specific immunoassay to measure inhibition of fibril growth. (<bold>B</bold>) Corresponding dose-response curves for <bold>8</bold> (top) and <bold>10</bold> (bottom) using a FlAsH fluorescence assay to measure inhibition of fibril growth; IC<sub>50</sub> is mean&#8201;&#177;&#8201;std from two independent experiments. Note that the immunoassay detects both seeds and new fibril growth while the FlAsH assay detects only new fibril growth, accounting for differences in the apparent maximum reduction in signal by compounds.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e716" position="float" orientation="portrait" xlink:href="41598_2025_17658_Fig3_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec6"><title>Fibril growth inhibition observed by ThioT fluorescence</title><p id="Par16">We further evaluated whether fibril growth inhibition by our lead compounds can be measured with ThioT fluorescence, which has been widely used in previous studies of fibril growth inhibitors. Due to the low sensitivity of ThioT, we increased our fibril seed concentration to 3 &#181;M and utilized continuous shaking for 20&#160;hours to achieve measurable fibril growth. In our initial control experiments, we observed that compounds <bold>8</bold> and <bold>10</bold> reduced ThioT fluorescence in the presence of fibrils (Supplementary Fig. 7A), potentially due to either quenching or competition with ThioT binding to fibrils. In competition binding assays measuring ThioT fluorescence in the presence of fibrils (Supplementary Fig.&#160;8), we also observed a small but significant decrease in ThioT fluorescence at high concentrations of fibrils, but are not able to determine whether this is related to competitive displacement of ThioT or alternatively fluorescence quenching mediated by compounds interacting with fibrils at distinct binding sites. We also did not observe that increasing the concentration of fibril ends by sonicating the fibrils altered the effect of the compounds on ThioT fluorescence, indicating that it is not mediated by competition between ThioT and compounds at the ends of the fibrils.</p><p id="Par17">To address the potential for this effect to interfere with measurements of fibril growth, we used centrifugation and washing to isolate fibrils from compounds following the growth reaction. We then resuspended the fibril pellet in buffer containing ThioT (18 &#181;M) to measure fibril growth. This protocol substantially reduced the quenching or inhibitory effect of the compounds on ThioT fluorescence (Supplementary Fig.&#160;7B). We observed that compounds <bold>8</bold> and <bold>10</bold> significantly inhibited fibril growth (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A).</p><p id="Par18">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><bold>ThioT fluorescence shows inhibition of fibril growth by compounds. (A)</bold> Measurement of fibril growth by ThioT fluorescence in the presence of <bold>8</bold> and <bold>10 at</bold> 30&#181;M and 100&#181;M respectively, after serial centrifugation and washing. There is significant fibril growth inhibition seen at both concentrations of <bold>8</bold> and <bold>10</bold> (t-test, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). Graphs show data points (<italic toggle="yes">n</italic>&#8201;=&#8201;3) with mean (bars) and std (error bars). Similar results were observed in three independent experiments. <bold>(B)</bold> Plot of fluorescence readings over time for a kinetic seeded assay measuring ThioT fluorescence in the absence or presence of <bold>8</bold> and <bold>10 at</bold> 30&#181;M and 100&#181;M respectively with continuous orbital shaking for 48&#160;h. The Line represents smoothed data averaging over 3 neighboring data points. <bold>(C)</bold> Lag time measurements are graphed for each condition in the seeded kinetic assay, defined by the time point at which fluorescence intensity increases by 20% above the baseline. There is significant increase in lag time seen at both concentrations of <bold>8</bold> and <bold>10</bold> (t-test, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Graphs show mean (data points) plus std (error bars). Similar results were observed from three independent experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e791" position="float" orientation="portrait" xlink:href="41598_2025_17658_Fig4_HTML.jpg"/></fig>
</p><p id="Par19">Given the challenges with this assay relying on endpoint ThioT measurements, we next performed a kinetic fibril growth assay with 1&#181;M fibril seeds, 6&#181;M asyn monomer and ThioT, utilizing continuous shaking in a plate reader in the presence or absence of compound. Under these assay conditions, we do not observe linear fibril growth based on ThioT fluorescence, but instead observe a lag phase followed by a substantial rise in ThioT fluorescence suggesting a rapid increase in fibril growth, followed by a plateau. We observed that compounds <bold>8</bold> and <bold>10</bold> inhibit both the duration of the lag phase as well as the rate at which ThioT fluorescence increases following the longer lag period (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B and C, Supplementary Fig.&#160;9).</p><sec id="Sec7"><title>Dimethoxyphenyl piperazine compounds also inhibit the growth of fibrils amplified from LBD postmortem brain tissue</title><p id="Par20">Emerging studies have shown that the structure of asyn fibrils derived from postmortem LBD brain tissue differs substantially from the structures of fibrils produced in vitro from recombinant protein<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup>. Differences in structure among these distinct fibril conformers may affect the binding and inhibition of fibril growth by small molecule compounds. Compounds <bold>8 and 10</bold> were initially identified based on in vitro fibrils. We recently generated amplified LBD fibrils using fibrils extracted from LBD brain tissue, and showed that the fold of the LBD amplified fibrils matched the fold of asyn fibrils directly extracted from PD and LBD brain tissue<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. We utilized amplified LBD fibril seeds in the same fibril growth assay to test these lead analogs<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Compounds <bold>8</bold> and <bold>10</bold> showed similar IC<sub>50</sub> values to those obtained for in-vitro assembled fibril seeds (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). This result indicates that compounds <bold>8</bold> and <bold>10</bold> can inhibit the growth of fibrils that are structurally similar to those accumulating in PD and LBD.</p><p id="Par21">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Fibril growth inhibition by the lead compounds is also observed for LBD-amplified fibrils. The dose-response curves of <bold>8</bold> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref><bold>A</bold>) and <bold>10</bold> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref><bold>B</bold>) in FlAsH fibril growth assays using fibrils amplified from LBD brain tissue. Graphs show mean (data points) plus std (error bars). Similar results were observed from two independent experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e869" position="float" orientation="portrait" xlink:href="41598_2025_17658_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec8"><title>Docking studies suggest a potential mechanism for fibril growth Inhibition</title><p id="Par22">Small molecule compounds can potentially bind to fibrils or monomeric proteins in many different ways. When binding to the fibrils, the small molecule can bind to the highly ordered beta sheet region or, less likely, to the disordered N-terminal or C-terminal regions. To explore potential modes of interaction for inhibitor compounds, we utilized molecular docking software, Autodock Vina<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>to predict potential binding sites of the inhibitor compounds on LBD asyn fibrils (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>, Supplementary Fig.&#160;10). We focused on LBD fibrils (PDB ID: 8a9l) as a docking substrate since this structure was determined for asyn fibrils extracted from postmortem human brain tissue. SSNMR studies indicated that the structure of amplified LBD fibrils (PDB ID: 8fpt) is highly similar to 8a9l, but were not able to resolve the structural conformation of the E46-V66 region<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. A structural model for our in vitro asyn fibrils is currently being refined based on single particle cryo-EM and solid-state NMR data but is not yet available for docking studies. To maximize the effect of observing binding to fibril ends in parallel or perpendicular to the fibril axis, we Limited our docking substrate to 5 fibril units, which is sufficient to also identify binding sites spanning multiple monomeric units along the fibril surface.</p><p id="Par23">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Binding sites predicted by molecular docking for compounds <bold>10</bold> and <bold>8</bold>. In the examples shown in A-D, compound binding sites are on the surface of the elongating ends of fibrils, where they could inhibit binding of monomeric asyn required for elongation. Example docking sites of <bold>10</bold> (top 2 panels, A and B) and <bold>8</bold> (bottom 2 panels, C and D) on LBD asyn fibrils (8a9l).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e910" position="float" orientation="portrait" xlink:href="41598_2025_17658_Fig6_HTML.jpg"/></fig>
</p><p id="Par24">Among binding sites with the lowest predicted binding energy for the two example compounds, we observed several poses on the surface of the elongating ends of the fibrils, which indicate a &#8220;capping&#8221; mechanism of inhibition where the compounds compete with the binding of monomeric asyn during elongation. Six of the nine docked sites for <bold>8</bold> and four of the nine sites for <bold>10</bold> are located on the surface of the elongating end of the fibril (Supplementary Fig.&#160;8). Interestingly for these binding sites, the compounds interact with one beta-strand and are oriented along the peptide backbone. The piperazine interacts with the backbone, while the aromatic groups on the left-hand and right-hand sides interact with the backbone and side chains. The interaction of the compounds with the elongating end may constrain the ability of additional monomers to align with the beta sheet conformation of the fibril seed, thus decreasing the rate of monomer association required for fibril growth. The alternative docked binding sites are along the fibril surface, parallel to the z axis, spanning 3 to 4 monomeric units (Supplementary Fig.&#160;10). Moreover, in some of these binding sites that are parallel to the z axis, the methoxy subgroups of the aromatic groups (left-hand or right-hand side) interact with fibril ends, which may also constrain the ability of additional monomers to attach to the elongating end.</p></sec></sec><sec id="Sec9"><title>Discussion</title><p id="Par25">This work optimized a fibril growth assay utilizing FlAsH fluorescence to screen and identify small molecule compounds that inhibit asyn fibril growth. The method enables the discovery of new compounds by measuring asyn fibril growth over short time periods (3&#160;h), using low concentrations of fibril seeds and monomer, where fibril growth is linear with respect to time<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.</p><p id="Par26">We obtained an IC<sub>50</sub> value for EGCG in our FlAsH fluorescence assay that is similar to IC<sub>50</sub> values previously obtained using ThioT to measure inhibition of asyn fibril growth<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. Using our FlAsH fluorescence assay, we identified a family of dimethoxyphenyl piperazine compounds capable of inhibiting fibril growth in-vitro. Fibril growth inhibition was further validated with two ThioT fluorescence assays and an asyn conformation-specific immunoassay. The four assays produced similar results, but the FlAsH fluorescence assay can detect smaller changes in fibril growth over shorter periods of time and with greater precision. This is partly due to the absence of signal and noise from fibril seeds that do not contain C2-tags. The immunoassay and ThioT assays detect initial fibril seeds as well as fibril growth, and hence, are less sensitive to small amounts of fibril growth that occurs in 3&#160;hours. To compensate for these limitations, we increased the concentration of fibril seeds and monomer, and extended the incubation time (20&#160;hours), in both the immunoassay and ThioT fluorescence experiments. The changes in fibril concentration measured under these modified assay conditions may reflect other molecular events in addition to fibril elongation, including primary or secondar nucleation of oligomeric intermediates and conversion to fibrils. In the case of our modified kinetic assay that utilizes shaking in a plate reader and intermittent ThioT fluorescence measurements, where we observe a lag phase followed by a rapid rise in fibril concentration, a combination of nucleation events, intermittent fibril fragmentation and elongation of fibrils may best explain the changes in fibril concentration. The observed inhibition by compounds <bold>8</bold> and <bold>10</bold> in these additional assays indicates that these compounds can effectively inhibit fibril accumulation in a variety of assay formats.</p><p id="Par27">Our previous studies identified multiple locations where a single amino acid difference between monomeric asyn and fibril seeds can substantially alter the fibril growth rate<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. Some amino acid residues within the beta-sheet region may be more important than others for determining the rate at which monomeric asyn associates with the elongating end of the fibril, since some amino acid changes had no effect on growth rates. These previous studies of fibril growth indicate that elongation requires specific conformational alignments as each monomeric unit associates with the fibril end. They also suggest that interaction of a small molecule compound with only two or three amino acid residues in either the fibril end or monomeric asyn has the potential to inhibit elongation.</p><p id="Par28">Our docking studies indicate that dimethoxyphenyl piperazine compounds may inhibit fibril growth by binding to fibril ends at the elongating surface of fibrils and inhibiting the association of additional monomers. However, it is also possible that the compounds bind to monomeric asyn in ways that inhibit its association with fibrils or interfere with a conformational change required to associate with the fibril end. Other previously identified small molecules such as EGCG inhibit fibril growth by interacting with monomer and sequestering it through the formation of off-pathway oligomers to prevent association with elongating fibrils<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. We observe an increase in FlAsH signal with incubation of monomeric asyn with EGCG, which is likely related to formation of oligomeric species. In contrast, FlAsH assays do not indicate the formation of oligomeric species when monomeric asyn is incubated with the dimethoxyphenyl piperazine compounds. Potential mechanisms based on interaction with either fibrils or monomer may be difficult to distinguish through further kinetic studies with varying concentrations of monomer or fibrils. For example, increasing monomer concentration may decrease the IC<sub>50</sub> for compound inhibition by increasing the number of binding sites available on monomer or alternatively by promoting greater competition of monomer with compound at binding sites on fibril ends. Increasing fibril seed concentration may increase the number of binding sites available on fibril ends but may not change IC<sub>50</sub> if it does not reduce free monomer concentration and also may not change the IC<sub>50</sub> if compound is binding to monomer. Future studies using cryo-EM, NMR and radioligand binding assays with radiolabelled compounds of interest could provide additional information about binding sites and potential mechanisms. Further structural understanding of binding sites on fibrillar and monomeric asyn can guide the optimization of compound structure to improve potency.</p><p id="Par29">This study&#8217;s limitation is that compounds were identified using in-vitro assays and have not been validated in cellular or in-vivo environments, where other mechanisms of fibril accumulation or clearance may be important. Studies of uptake and metabolism will also be required to optimize the potency of compound inhibition in cellular and in-vivo models.</p><p id="Par30">To date, there have been several pre-clinical and clinical studies focusing on small molecules that prevent asyn fibril accumulation. EGCG, which has been shown to inhibit asyn fibril growth, failed to show a protective effect in participants with multiple systems atrophy, another synucleinopathy (phase 3, PROMESA trial). This could be due to the limited blood-brain-barrier penetration of EGCG<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. Other small molecules currently in phase 2 trials include a pyrazino-pyrimidine NTP200-11 (UCB0599, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04658186">NCT04658186</ext-link>)<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup> and herbal ethanolic extract MT101-5 (Mthera Pharma Co, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06175767">NCT06175767</ext-link>)<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. There are ongoing efforts to study the tolerability of small molecules of a pyrazole moiety Anle138b(MODAG GmbH, phase 1 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04685265">NCT04685265</ext-link>) that have been shown to decrease asyn aggregation in the presence of lipids<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. Furthermore, there have been promising results from preclinical studies of small molecule compound SynuClean-D in vitro and in human neuroglioma cells<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup> and with molecular tweezers (Clr01) in-vitro and in mouse models<sup><xref ref-type="bibr" rid="CR57">57</xref>&#8211;<xref ref-type="bibr" rid="CR60">60</xref></sup>. With further optimization and validation, our assay may be suitable for high throughput screening of compound libraries to identify additional new leads for this PD therapeutic approach. Although the compounds identified here appear equally potent in assays with in vitro and LBD asyn fibrils, there may be advantages to utilizing asyn fibrils derived from postmortem LBD tissue in fibril growth assays as a primary screening approach for small molecule inhibitors. Our previous studies indicate that different asyn fibril conformers have distinct structural requirements for fibril growth, and identified several amino acid residues that are critical for LBD asyn fibril growth but not for in vitro fibrils. Future studies to understand how the compounds identified here and in other studies inhibit LBD asyn fibril growth may also provide further guidance for optimizing inhibition potency in efforts to develop effective mechanism-based therapeutics targeting asyn fibril accumulation in PD.</p></sec><sec id="Sec10"><title>Conclusion</title><p id="Par31">Asyn fibril growth is a process that can be targeted to prevent the progressive accumulation of asyn fibrils in PD. Our assay provides a platform for identifying potent asyn fibril growth inhibitors. Ultimately, these small molecules could be further developed as disease-modifying therapies for PD.</p></sec><sec id="Sec11"><title>Methods and materials</title><sec id="Sec12"><title>Compounds</title><p id="Par32">Compounds were purchased from Chembridge (San Diego, California USA) and Vitas-M Laboratory (Hong Kong). They were dissolved in DMSO at a concentration of 10mM and stored at &#8722;20&#160;&#176;C.</p></sec><sec id="Sec13"><title>Preparation of Recombinant WT-asyn, C2-WT-asyn and Asyn fibrils</title><p id="Par33">Untagged WT-asyn monomer, C2-tagged WT-asyn monomer, and asyn fibrils were prepared as described<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Briefly, asyn protein was expressed in E. Coli (BL21-CodonPlus (DE3)-RIL Competent Cells, Agilent Catalog: 230245) using the pRK172 plasmid expressing the asyn sequence. Bacteria were grown in TB broth containing 50&#160;&#181;g/ml ampicillin overnight with shaking. Asyn monomeric protein was extracted using osmotic shock followed by heat denaturation and ion-exchange chromatography. Purified asyn monomer was stored at &#8722;80&#160;&#176;C until use.</p><p id="Par34">WT-asyn and C2-WT-asyn fibrils were made by incubating 2&#160;mg/ml of WT-asyn protein or C2-WT-asyn protein, respectively, in 20 mM Tris-HCl, pH 8.0 plus 100 mM NaCl buffer with shaking at 1000&#160;rpm in an Eppendorf thermomixer set to 37&#160;&#176;C. Fibrils were stored at 4&#160;&#176;C until use. The concentration of asyn monomer and fibrils was determined using a micro-BCA assay performed according to the manufacturer&#8217;s instructions. Briefly, we utilized the micro-BCA assay (Thermo Fisher, Catalog number 23235) to estimate the amount of fibrils. A standard curve (200&#160;&#181;g/ml to 0.5&#160;&#181;g/ml) using manufacturer supplied diluted albumin (BSA) standard was used to determine concentration of asyn. The working reagent was made by mixing 25 parts of Micro BCA Reagent MA, 24 parts Reagent MB, and 1 part of Reagent MC (25:24:1, Reagent MA: MB: MC). In a microplate well, 150&#181;L of each standard or unknown sample (three replicates) was added along with 150&#160;&#181;l of the working reagent. The plate was incubated for 2&#160;h at 37&#160;&#176;C, cooled for 10&#160;min and absorbance measured at 562&#160;nm on a plate reader. The amplified fibrils were centrifuged at 21,000&#160;g for 15&#160;min at 4&#160;&#176;C to separate fibrils from monomer. The supernatant and total sample containing fibrils plus unincorporated monomer was also assessed. The measured decrease in asyn monomer concentration between total and supernatant was used to determine the concentration of fibrils.</p></sec><sec id="Sec14"><title>Preparation of LBD amplified fibrils</title><p id="Par35">The Movement Disorders Brain Bank, Washington University, St. Louis, MO, provided well-characterized postmortem frozen brain tissue of de-identified participants. Written informed consent to perform a brain autopsy for research purposes was obtained from participants of the Movement Disorders Brain Bank. After death, the immediate next-of-kin were contacted and confirmed consent for brain removal and retention of brain tissue for research purposes. The participant who donated brain tissue used in these experiments participated in a clinical study approved by the Human Research Protection Office at Washington University prior to autopsy. All methods using human autopsy-derived material were carried out in accordance with relevant guidelines and regulations.</p><p id="Par36">Fibril growth inhibition assays used amplified fibrils from case LBD1 as published previously<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. Human postmortem brain tissue samples were sequentially extracted in buffers of increasing detergent strength using a Dounce Homogenizer to generate LBD-derived insoluble fraction seeds. The LBD seeds were combined with purified asyn monomer and subjected to 6 cycles of fragmentation followed by quiescent incubations to generate amplified fibrils<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>.</p></sec><sec id="Sec15"><title>Fibril growth assay utilizing flash fluorescence measurements</title><p id="Par37">The fibril growth assay was performed similarly to previously published methods<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. Briefly, fibril samples at 1&#181;M concentration in fibril buffer were either sonicated for 5&#160;min at amplitude 50 in a cup horn sonicator (Qsonica 600) for the recombinant WT- or C2- fibrils for 1&#160;min at amplitude 50 for the LBD-derived fibrils and mixed with 3&#181;M of C2-asyn monomer and compound at a range of concentrations in 20 mM Tris-HCl pH 8.0, 100 mM NaCl buffer with 50 &#181;L total volume. Compounds were dissolved in DMSO and the final concentration of DMSO was kept constant at 1.25%. The seeds, asyn monomer, and various concentrations of the compounds of interest were quiescently incubated for 3&#160;h at 37&#160;&#176;C in Corning Black 96-well plates (Fisher, catalog no. 07-200-762). After 3&#160;h, a 50 &#181;L FlAsH assay mixture consisting of 7 mM tris(2-carboxyethyl)phosphine, 2 mM EDT, 2 mM EDTA, 50 nM FlAsH-EDT2 (Invitrogen TC-FlAsH II in-cell tetracysteine tag detection kit, catalog no. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="T34561">T34561</ext-link>), and 400 mM Tris-HCl, pH 8.0 was added and the total 100 &#181;L mixture incubated for additional 1&#160;h at room temperature. FlAsH fluorescence was detected in a BioTek plate reader using a 485/20-nm excitation filter, a 528/20-nm emission filter, top 510-nm optical setting, and gain setting 100. Measurements were performed in triplicates. Dose-dependent curve fit a four-parameter logistic curve, Y&#8201;=&#8201;Bottom + (Top-Bottom)/(1&#8201;+&#8201;10^((LogIC<sub>50</sub>-X)*HillSlope)) to determine IC<sub>50</sub>. Mean IC<sub>50</sub> was calculated from 2 to 3 experiments performed on different days. Maximum inhibition is calculated as (Intensity<sub><italic toggle="yes">100 &#181;M</italic></sub>-Intensity<sub><italic toggle="yes">0&#181;M</italic></sub>)/Intensity<sub><italic toggle="yes">0&#181;M</italic></sub> x 100% where Intensity<sub><italic toggle="yes">100&#181;M</italic></sub> and Intensity<sub><italic toggle="yes">0&#181;M</italic></sub> is the intensity at 100&#181;M of compound and intensity with no compound in the presence of fibrils and monomers.</p></sec><sec id="Sec16"><title>Measurement of quenching</title><p id="Par38">Experiments to evaluate quenching were performed with 1 &#181;M fibrils assembled from C2-WT-asyn plus 100 &#181;M compound in the absence of monomer. Fibril seeds and compound were incubated for 30&#160;min in 20 mM Tris-HCl pH 8.0, 100mM NaCl buffer (50 &#181;L total volume), and then 50 &#181;L FlAsH fluorescence assay mixture was added as above and incubated for an additional 1&#160;h at room temperature. FlAsH fluorescence was detected in a BioTek plate reader using a 485/20-nm excitation filter, a 528/20-nm emission filter, top 510-nm optical setting, and gain setting 100. Percent quenching is calculated as 100% - (Intensity<sub>100 &#181;M</sub>/Intensity<sub>0&#181;M</sub>).</p></sec><sec id="Sec17"><title>Measurement of native fluorescence</title><p id="Par39">Experiments to evaluate native fluorescence were performed with 100 &#181;M compound alone in the absence of fibril seeds and monomer. In a similar manner, compounds were incubated for 30&#160;min in 20&#160;mm Tris-HCl pH 8.0, 100mM NaCl buffer (50 &#181;L total volume) and then 50 &#181;L FlAsH fluorescence assay mixture was added as above and incubated for an additional 1&#160;h at room temperature. FlAsH fluorescence was detected in a BioTek plate reader using a 485/20-nm excitation filter, a 528/20-nm emission filter, top 510-nm optical setting, and gain setting 100. Percent native fluorescence is calculated as 100% x Intensity<sub>100 &#181;M</sub>/intensity<sub>_DMSObuffer</sub>, with Intensity<sub>100 &#181;M</sub> as the intensity of 100&#181;M compound in the absence of monomer and fibrils and intensity_<sub>DMSObuffer</sub> is the background intensity of buffer.</p></sec><sec id="Sec18"><title>Sandwich ELISA</title><p id="Par40">Sandwich ELISA was performed similarly to previously published methods<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. Briefly, anti-alpha-synuclein antibody [MJFR-14-6-4-2] (Abcam ab209538) was used as capture antibody and diluted to 1 &#181;g/mL in 34 mM sodium bicarbonate, 16 mM sodium carbonate solution with 3 mM sodium azide. The capture antibody solution was added to a 96-well plate (50 &#181;L/well) and incubated overnight at 4&#176;C. Plates were washed 5X with 150 &#181;L 1XPBS&#8201;+&#8201;0.05% Tween-20/well in between each step. Plates were blocked with 150 &#181;L of 2% BSA (Sigma-Aldrich #A7906) in PBS at 37&#8201;&#176;C for 2 hours. Before standard and sample addition, plates were washed as previously stated. Samples were diluted at 1:10,000 in sample buffer containing no SDS to reach an SDS concentration of 0.06%. Standards and samples were added to the plate 50 &#181;L/well in duplicate wells and incubated overnight at 4&#8201;&#176;C with slow rotation. The detection antibody (13G5B, in-house) solution was diluted to a final concentration of 1 &#181;g/mL in PBS&#8201;+&#8201;0.05% BSA&#8201;+&#8201;0.05% Tween. The detection antibody solution was added 50&#181;L/well and incubated at 37&#8201;&#176;C for 2 hours. Streptavidin poly-HRP80 (Fitzgerald # 65R-S118) was diluted 1:8000 in 1% BSA in 1XPBS&#8201;+&#8201;0.05% Tween-20. The streptavidin solution was added 50 &#181;L/well and incubated for 90 minutes at room temperature in the dark. The plate was washed as described previously. Fifty &#181;L/well of 3,3&#8217;,5,5&#8217;-Tetramethylbenzidine Liquid Substrate, Super Slow (Sigma # T5569) was rocked on the rotator until the first reading. Readings were done on Synergy 2 (BioTek) at 650 nM at 9, 12, and 15&#160;min. The time point with the highest ratio between the top concentration and 0 concentration (background) in the standard curve was chosen for data analysis. Dose-dependent curve fit a four-parameter logistic curve, Y&#8201;=&#8201;Bottom + (Top-Bottom)/(1&#8201;+&#8201;10^((LogIC<sub>50</sub>-X)*HillSlope)) to determine IC<sub>50</sub>. Mean IC<sub>50</sub> calculated from 2 experiments.</p></sec><sec id="Sec19"><title>ThioT fluorescence assay for fibril growth</title><p id="Par41">The first ThioT fibril growth assay was performed similarly to that of the FlAsH fluorescence assay with a few modifications. Fibril samples (3 &#181;M concentration) were sonicated for 5&#160;min at amplitude 50 in a cup horn sonicator (Qsonica 700) and mixed with 6&#181;M of C2-asyn monomer and compound at 30 &#181;M and 100 &#181;M in 20&#160;mm Tris-HCl pH 8.0, 100&#160;mm NaCl buffer with 100 &#181;L total volume. Compounds were dissolved in DMSO and the final concentration of DMSO was kept constant at 1.25%. The seeds, asyn monomer, and concentrations of the compounds of interest were incubated for 20&#160;h at 37&#160;&#176;C in Eppendorf Thermomixer R at 1000&#160;rpm in ultracentrifuge tubes. After 20&#160;h, the assay mixture volume (100 &#181;L) was increased to 300 &#181;L with fibril buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl buffer) and centrifuged for 100,000&#215;g for 20&#160;min at 4&#8451;. The supernatant (270 &#181;L) was removed and replaced with 270 &#181;L fibril buffer. 300 &#181;L total volume was again centrifuged at 100,000&#215;g for 20&#160;min at 4&#8451;. Again, the supernatant (270 &#181;L) was removed, the seeds were recovered and mixed with 50 &#181;L fibril buffer with 0.1% Triton. The 80&#181;L sample was placed into a Corning Black 96-well plates (Fisher, catalog no. 07-200-762) and incubated with 18 &#181;M ThioT in Fibril Buffer. A total volume of 160&#160;&#181;l/well was incubated at room temperature for 24&#160;h at 200&#160;rpm in a Benchmark Scientific Incumixer. After 24&#160;h, ThioT fluorescence was measured in a BioTek plate reader using a 440/30-nm excitation filter, a 485/20-nm emission filter, and top 50% optical setting. % Fibril Growth without compound is calculated by (Intensity Measurement &#8211; Intensity_fibrils_only)/(Intensity_nocompound - Intensity_fibril_only), where Instensity_fibril_only is the average intensity of fibrils in the absence of monomer and compounds, Intensity_ nocompound is the average intensity of fibrils incubated with monomers in the absence of compounds.</p><p id="Par42">The kinetic seeded ThioT fibril growth assay was performed similarly except that 1 &#181;M in vitro asyn fibrils were sonicated for 5&#160;min at amplitude 50 in a cup horn sonicator (Qsonica 700) and mixed with 6&#181;M of C2-asyn monomer, compound at 30 &#181;M and 100 &#181;M in 20&#160;mm Tris-HCl pH 8.0, 100&#160;mm NaCl buffer, and 18&#181;M ThioT with 100 &#181;L total volume in a Corning Black 96-well plates (Fisher, catalog no. 07-200-762) and. Compounds were again dissolved in DMSO and the final concentration of DMSO was kept constant at 1.25%. The compound, monomer, asyn fibril and ThioT mixtures were pre-incubated for 30&#160;min at room temperature. Then, the plate was placed into BioTek Synergy H1 plate reader for read and continuous orbital rotation (180&#160;cpm). Read speed was set at normal with 2000 msec delay and 30 measurements/data point. ThioT Fluorescence was measured using filter set 1 (excitation 440, emission 485, optics: top, gain 100) at 30&#160;min intervals over 48&#160;h. Averaged intensity is plotted after subtraction of values for wells containing buffer only. A 0th order polynomial fit was used to smooth the data by averaging 3 data point neighbours using the method of Savistsky and Golay in GraphPad Prism. Lag time was calculated as the time it takes to deviate 20% from the running mean. Initial slope, or the rate of ThioT fluorescence increase, was taken for 3&#160;h after the lag time or from the lag time until the end of the experiment (48&#160;h). If the fluorescence did not deviate from the running mean and there was no lag time, the slope was taken for the last 3&#160;h. Data points were performed in quadruplicates.</p></sec><sec id="Sec20"><title>ThioT competition assays</title><p id="Par43">Competition assays used a fixed 1&#181;M concentration of asyn fibrils and 3&#181;M of ThioT. The compound was diluted in 30mM Tris-HCl, pH7.4, 0.1% BSA and added to the reactions in various concentrations. Reactions were incubated at room temperature for 1.5&#160;h before quantifying bound compound as described above for saturation binding assay. Fluorescence was determined with a Biotek plate reader using a 440/30 excitation filter and a 485/20 emission filter. Data points were performed in triplicate. Nonspecific fluorescence was measured in parallel reactions containing ThioT plus each concentration of.</p><p id="Par44">competitor but without fibrils, and these measurements were subtracted.</p><p id="Par45">from the reactions with fibrils to yield fibril-specific fluorescence.</p></sec><sec id="Sec21"><title>Characterization of Asyn fibril growth products via negative stain TEM</title><p id="Par46">Negative staining of the asyn fibrils after 24&#160;h incubation with or without 6&#181;M compounds 8 and 10 was performed by applying a given fibril preparation to ultrathin Carbon 300 mesh Gold grids (Catalog 01824 G, Ted Pella). The grids were negatively glow discharged (13&#160;mA, 45&#160;s) using GloQube glow discharge system (Model #025235 EMS). A 10&#160;&#181;l fibril sample at appropriate dilution was applied to the glow discharged grid for 5&#160;min with the carbon side facing the sample drop. Post-sample incubation, the grid was washed (6 times) with 50&#160;&#181;l of H2O, washed once with 50&#160;&#181;l of 0.75% uranyl formate and stained with 50&#160;&#181;l of 0.75% uranyl formate for 3&#160;min. The grids were blotted using filter paper, leaving a small amount of stain to air dry on the grid surface. Grids were imaged on a JEOL 1400 TEM operating at 120&#160;kV to visualize the negatively stained fibrils.</p></sec><sec id="Sec22"><title>Molecular Docking</title><p id="Par47">Compound structures were downloaded as 3D SDF files (Chembridge, Vitas M Laboratory). Molecular blind docking studies were performed via Autodock Vina v1.2.x<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> (Scripps, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vina.scripps.edu/">https://vina.scripps.edu/</ext-link>) and viewed with Pymol (pymol.org). The structure of LBD-derived asyn fibrils determined by single particle cryo-EM (PDB ID: 8a9l)<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> were obtained from RCSB protein data bank (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>) as a target protein for blind docking. We increased the LBD-derived asyn structure 8a9l to 5 fibril units using RELION<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>and kept only the beta-sheet regions aa 31&#8211;100. Water molecules and nonpolar hydrogens were removed from all compounds and protein structures. A grid box with a dimension of 126&#8201;&#215;&#8201;126&#8201;&#215;&#8201;126 &#197;<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> was applied to all asyn structures, and center x&#8201;=&#8201;86.868, y&#8201;=&#8201;95.080, and z&#8201;=&#8201;97.452 were applied for 8a9l. Energy range was set to 4 and exhaustiveness was set to 8 (default values).</p></sec></sec><sec id="Sec23" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17658_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Rebecca L. Miller, Jennifer Y. O&#8217;Shea, and Aditi Bagade for helpful discussions. We also thank Katherine Basore for generating the 5 asymmetric unit model of 8A9L used for docking experiments.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization and Study Design: PTK, NJC, JMB, HH; Method development: HH, DDD, SJW, PTK; Acquisition of data: HH, DDD, SJW, AG; Analysis and interpretation of data: HH, DDD, PTK; Drafting of the manuscript: HH, DDD, PTK; Critical review and revision of the manuscript: HH, DDD, PTK, NJC, SJW.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information files. Raw data files are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par48">Competing Interests Statement: Authors HH, DDD, and PTK have a pending patent application &#8220;Compounds that Inhibit Alpha-Synuclein Fibril Growth for the Treatment of Parkinson&#8217;s Disease&#8221;. Patent applicant: Washington University in St. Louis, Name of inventors: Paul T. Kotzbauer, Helen Hwang, and Dhruva D. Dhavale. Status of application: Pending. The patent application covers the dimethyoxyphenyl piperazine and related compounds that can inhibit asyn fibril growth. In addition, authors DDD and PTK have a pending patent application titled &#8220;Tissue-Seeded Fibrils and Methods of Making and Using Same&#8221;. Patent applicant: Washington University in St. Louis, Name of inventors: Paul T. Kotzbauer, Dhruva D. Dhavale, Rebecca Miller and Jennifer Y. O&#8217;Shea, Application number: 17/858817, Status of application: Pending. The patent application covers the process of generating amplified fibrils, its methods and composition. Authors DDD and PTK are founders of Helical Biosciences LLC and have an ownership interest in the company. Other authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>Alpha-synuclein and neurodegenerative diseases</article-title><source>Nat. Rev. Neurosci.</source><year>2001</year><volume>2</volume><fpage>492</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/35081564</pub-id><pub-id pub-id-type="pmid">11433374</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Goedert, M. Alpha-synuclein and neurodegenerative diseases. <italic toggle="yes">Nat. Rev. Neurosci.</italic><bold>2</bold>, 492&#8211;501 (2001).<pub-id pub-id-type="pmid">11433374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35081564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newberry</surname><given-names>RW</given-names></name><name name-style="western"><surname>Leong</surname><given-names>JT</given-names></name><name name-style="western"><surname>Chow</surname><given-names>ED</given-names></name><name name-style="western"><surname>Kampmann</surname><given-names>M</given-names></name><name name-style="western"><surname>DeGrado</surname><given-names>WF</given-names></name></person-group><article-title>Deep mutational scanning reveals the structural basis for &#945;-synuclein activity</article-title><source>Nat. Chem. Biol.</source><year>2020</year><volume>16</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-0480-6</pub-id><pub-id pub-id-type="pmid">32152544</pub-id><pub-id pub-id-type="pmcid">PMC7339969</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Newberry, R. W., Leong, J. T., Chow, E. D., Kampmann, M. &amp; DeGrado, W. F. Deep mutational scanning reveals the structural basis for &#945;-synuclein activity. <italic toggle="yes">Nat. Chem. Biol.</italic><bold>16</bold>, 653&#8211;659 (2020).<pub-id pub-id-type="pmid">32152544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-020-0480-6</pub-id><pub-id pub-id-type="pmcid">PMC7339969</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jao</surname><given-names>CC</given-names></name><name name-style="western"><surname>Der-Sarkissian</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Langen</surname><given-names>R</given-names></name></person-group><article-title>Structure of membrane-bound &#945;-synuclein studied by site-directed spin labeling</article-title><source>Proc. Natl. Acad. Sci.</source><year>2004</year><volume>101</volume><fpage>8331</fpage><lpage>8336</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400553101</pub-id><pub-id pub-id-type="pmid">15155902</pub-id><pub-id pub-id-type="pmcid">PMC420394</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Jao, C. C., Der-Sarkissian, A., Chen, J. &amp; Langen, R. Structure of membrane-bound &#945;-synuclein studied by site-directed spin labeling. <italic toggle="yes">Proc. Natl. Acad. Sci.</italic><bold>101</bold>, 8331&#8211;8336 (2004).<pub-id pub-id-type="pmid">15155902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0400553101</pub-id><pub-id pub-id-type="pmcid">PMC420394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulmer</surname><given-names>TS</given-names></name><name name-style="western"><surname>Bax</surname><given-names>A</given-names></name><name name-style="western"><surname>Cole</surname><given-names>NB</given-names></name><name name-style="western"><surname>Nussbaum</surname><given-names>RL</given-names></name></person-group><article-title>Structure and dynamics of micelle-bound human &#945;-synuclein</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>9595</fpage><lpage>9603</lpage><pub-id pub-id-type="doi">10.1074/jbc.M411805200</pub-id><pub-id pub-id-type="pmid">15615727</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ulmer, T. S., Bax, A., Cole, N. B. &amp; Nussbaum, R. L. Structure and dynamics of micelle-bound human &#945;-synuclein. <italic toggle="yes">J. Biol. Chem.</italic><bold>280</bold>, 9595&#8211;9603 (2005).<pub-id pub-id-type="pmid">15615727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M411805200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lashuel</surname><given-names>HA</given-names></name><name name-style="western"><surname>Overk</surname><given-names>CR</given-names></name><name name-style="western"><surname>Oueslati</surname><given-names>A</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E</given-names></name></person-group><article-title>The many faces of &#945;-synuclein: from structure and toxicity to therapeutic target</article-title><source>Nat. Rev. Neurosci.</source><year>2013</year><volume>14</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/nrn3406</pub-id><pub-id pub-id-type="pmid">23254192</pub-id><pub-id pub-id-type="pmcid">PMC4295774</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Lashuel, H. A., Overk, C. R., Oueslati, A. &amp; Masliah, E. The many faces of &#945;-synuclein: from structure and toxicity to therapeutic target. <italic toggle="yes">Nat. Rev. Neurosci.</italic><bold>14</bold>, 38&#8211;48 (2013).<pub-id pub-id-type="pmid">23254192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn3406</pub-id><pub-id pub-id-type="pmcid">PMC4295774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polymeropoulos</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Mutation in the &#945;-synuclein gene identified in families with parkinson&#8217;s disease</article-title><source>Sci. (80-)</source><year>1997</year><volume>276</volume><fpage>2045</fpage><lpage>2047</lpage><pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id><pub-id pub-id-type="pmid">9197268</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Polymeropoulos, M. H. et al. Mutation in the &#945;-synuclein gene identified in families with parkinson&#8217;s disease. <italic toggle="yes">Sci. (80-)</italic>. <bold>276</bold>, 2045&#8211;2047 (1997).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.276.5321.2045</pub-id><pub-id pub-id-type="pmid">9197268</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotzbauer</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Fibrillization of &#945;-synuclein and Tau in Familial parkinson&#8217;s disease caused by the A53T &#945;-synuclein mutation</article-title><source>Exp. Neurol.</source><year>2004</year><volume>187</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.01.007</pub-id><pub-id pub-id-type="pmid">15144854</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Kotzbauer, P. T. et al. Fibrillization of &#945;-synuclein and Tau in Familial parkinson&#8217;s disease caused by the A53T &#945;-synuclein mutation. <italic toggle="yes">Exp. Neurol.</italic><bold>187</bold>, 279&#8211;288 (2004).<pub-id pub-id-type="pmid">15144854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2004.01.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarranz</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>The new mutation, E46K, of &#945;-Synuclein causes Parkinson and lewy body dementia</article-title><source>Ann. Neurol.</source><year>2004</year><volume>55</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1002/ana.10795</pub-id><pub-id pub-id-type="pmid">14755719</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zarranz, J. J. et al. The new mutation, E46K, of &#945;-Synuclein causes Parkinson and lewy body dementia. <italic toggle="yes">Ann. Neurol.</italic><bold>55</bold>, 164&#8211;173 (2004).<pub-id pub-id-type="pmid">14755719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.10795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pujols</surname><given-names>J</given-names></name><etal/></person-group><article-title>Small molecule inhibits &#945;-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons</article-title><source>Proc. Natl. Acad. Sci.</source><year>2018</year><volume>115</volume><fpage>10481</fpage><lpage>10486</lpage><pub-id pub-id-type="doi">10.1073/pnas.1804198115</pub-id><pub-id pub-id-type="pmid">30249646</pub-id><pub-id pub-id-type="pmcid">PMC6187188</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Pujols, J. et al. Small molecule inhibits &#945;-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. <italic toggle="yes">Proc. Natl. Acad. Sci.</italic><bold>115</bold>, 10481&#8211;10486 (2018).<pub-id pub-id-type="pmid">30249646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1804198115</pub-id><pub-id pub-id-type="pmcid">PMC6187188</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pe&#241;a-D&#237;az</surname><given-names>S</given-names></name><etal/></person-group><article-title>The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple &#945;-synuclein strains</article-title><source>J Biol. Chem</source><year>2022</year><volume>298</volume><issue>5</issue><fpage>101902</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2022.101902</pub-id><pub-id pub-id-type="pmid">35390347</pub-id><pub-id pub-id-type="pmcid">PMC9079179</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Pe&#241;a-D&#237;az, S. et al. The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple &#945;-synuclein strains. <italic toggle="yes">J Biol. Chem</italic><bold>298</bold>(5), 10.1016/j.jbc.2022.101902. 101902 (2022).<pub-id pub-id-type="pmid">35390347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2022.101902</pub-id><pub-id pub-id-type="pmcid">PMC9079179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hideshima</surname><given-names>M</given-names></name><etal/></person-group><article-title>Two-step screening method to identify &#945;-synuclein aggregation inhibitors for parkinson&#8217;s disease</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>351</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-04131-9</pub-id><pub-id pub-id-type="pmid">35013421</pub-id><pub-id pub-id-type="pmcid">PMC8748996</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Hideshima, M. et al. Two-step screening method to identify &#945;-synuclein aggregation inhibitors for parkinson&#8217;s disease. <italic toggle="yes">Sci. Rep.</italic><bold>12</bold>, 351 (2022).<pub-id pub-id-type="pmid">35013421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-04131-9</pub-id><pub-id pub-id-type="pmcid">PMC8748996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fryml</surname><given-names>LD</given-names></name><etal/></person-group><article-title>The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status</article-title><source>J. Psychiatr Pract.</source><year>2017</year><pub-id pub-id-type="doi">10.1097/PRA.0000000000000237</pub-id><pub-id pub-id-type="pmid">28492457</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Fryml, L. D. et al. The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status. <italic toggle="yes">J. Psychiatr Pract.</italic>10.1097/PRA.0000000000000237 (2017).<pub-id pub-id-type="pmid">28492457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PRA.0000000000000237</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vittorio</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rational design of small molecules able to inhibit &#945;-synuclein amyloid aggregation for the treatment of parkinson&#8217;s disease</article-title><source>J. Enzyme Inhib. Med. Chem.</source><year>2020</year><volume>35</volume><fpage>1727</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1080/14756366.2020.1816999</pub-id><pub-id pub-id-type="pmid">32924648</pub-id><pub-id pub-id-type="pmcid">PMC7534360</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Vittorio, S. et al. Rational design of small molecules able to inhibit &#945;-synuclein amyloid aggregation for the treatment of parkinson&#8217;s disease. <italic toggle="yes">J. Enzyme Inhib. Med. Chem.</italic><bold>35</bold>, 1727&#8211;1735 (2020).<pub-id pub-id-type="pmid">32924648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14756366.2020.1816999</pub-id><pub-id pub-id-type="pmcid">PMC7534360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Murray, K. A. et al. Small molecules disaggregate alpha-synuclein and prevent seeding from patient brain-derived fibrils. <italic toggle="yes">Proc. Natl. Acad. Sci.</italic> 120, e2217835120 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2217835120</pub-id><pub-id pub-id-type="pmcid">PMC9963379</pub-id><pub-id pub-id-type="pmid">36757890</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elbatrawy</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Discovery of small molecule benzothiazole and Indole derivatives tackling Tau 2N4R and &#945;-synuclein fibrils</article-title><source>Bioorg. Med. Chem.</source><year>2024</year><volume>100</volume><fpage>117613</fpage><pub-id pub-id-type="doi">10.1016/j.bmc.2024.117613</pub-id><pub-id pub-id-type="pmid">38330847</pub-id><pub-id pub-id-type="pmcid">PMC10921547</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Elbatrawy, A. A. et al. Discovery of small molecule benzothiazole and Indole derivatives tackling Tau 2N4R and &#945;-synuclein fibrils. <italic toggle="yes">Bioorg. Med. Chem.</italic><bold>100</bold>, 117613 (2024).<pub-id pub-id-type="pmid">38330847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2024.117613</pub-id><pub-id pub-id-type="pmcid">PMC10921547</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamasaki</surname><given-names>TR</given-names></name><name name-style="western"><surname>Ono</surname><given-names>K</given-names></name><name name-style="western"><surname>Ho</surname><given-names>L</given-names></name><name name-style="western"><surname>Pasinetti</surname><given-names>GM</given-names></name></person-group><article-title>Gut microbiome-modified polyphenolic compounds inhibit &#945;-synuclein seeding and spreading in &#945;-synucleinopathies</article-title><source>Front. Neurosci.</source><year>2020</year><volume>14</volume><fpage>537139</fpage><pub-id pub-id-type="doi">10.3389/fnins.2020.00398</pub-id><pub-id pub-id-type="pmcid">PMC7212829</pub-id><pub-id pub-id-type="pmid">32431588</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Yamasaki, T. R., Ono, K., Ho, L. &amp; Pasinetti, G. M. Gut microbiome-modified polyphenolic compounds inhibit &#945;-synuclein seeding and spreading in &#945;-synucleinopathies. <italic toggle="yes">Front. Neurosci.</italic><bold>14</bold>, 537139 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.00398</pub-id><pub-id pub-id-type="pmcid">PMC7212829</pub-id><pub-id pub-id-type="pmid">32431588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>CH</given-names></name><name name-style="western"><surname>Saha</surname><given-names>R</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>C</given-names></name><name name-style="western"><surname>Bagchi</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>IA</given-names></name></person-group><article-title>Modulation of &#945;-Synuclein aggregation in vitro by a DNA aptamer</article-title><source>Biochemistry</source><year>2022</year><volume>61</volume><fpage>1757</fpage><lpage>1765</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.2c00207</pub-id><pub-id pub-id-type="pmid">35994742</pub-id><pub-id pub-id-type="pmcid">PMC9454088</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Tran, C. H., Saha, R., Blanco, C., Bagchi, D. &amp; Chen, I. A. Modulation of &#945;-Synuclein aggregation in vitro by a DNA aptamer. <italic toggle="yes">Biochemistry</italic><bold>61</bold>, 1757&#8211;1765 (2022).<pub-id pub-id-type="pmid">35994742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.2c00207</pub-id><pub-id pub-id-type="pmcid">PMC9454088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bieschke</surname><given-names>J</given-names></name><etal/></person-group><article-title>EGCG remodels mature &#945;-synuclein and amyloid-&#946; fibrils and reduces cellular toxicity</article-title><source>Proc. Natl. Acad. Sci.</source><year>2010</year><volume>107</volume><fpage>7710</fpage><lpage>7715</lpage><pub-id pub-id-type="doi">10.1073/pnas.0910723107</pub-id><pub-id pub-id-type="pmid">20385841</pub-id><pub-id pub-id-type="pmcid">PMC2867908</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Bieschke, J. et al. EGCG remodels mature &#945;-synuclein and amyloid-&#946; fibrils and reduces cellular toxicity. <italic toggle="yes">Proc. Natl. Acad. Sci.</italic><bold>107</bold>, 7710&#8211;7715 (2010).<pub-id pub-id-type="pmid">20385841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0910723107</pub-id><pub-id pub-id-type="pmcid">PMC2867908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Characterization of inhibitor-bound &#945;-synuclein dimer: role of &#945;-synuclein N-terminal region in dimerization and inhibitor binding</article-title><source>J. Mol. Biol.</source><year>2010</year><volume>395</volume><fpage>445</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2009.10.068</pub-id><pub-id pub-id-type="pmid">19895818</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Yamaguchi, Y. et al. Characterization of inhibitor-bound &#945;-synuclein dimer: role of &#945;-synuclein N-terminal region in dimerization and inhibitor binding. <italic toggle="yes">J. Mol. Biol.</italic><bold>395</bold>, 445&#8211;456 (2010).<pub-id pub-id-type="pmid">19895818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmb.2009.10.068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Caruana, G. et al. Inhibition and disaggregation of &#945;-synuclein oligomers by natural polyphenolic compounds. (2011).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.febslet.2011.03.046</pub-id><pub-id pub-id-type="pmid">21443877</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grelle</surname><given-names>G</given-names></name><etal/></person-group><article-title>Black tea Theaflavins inhibit formation of toxic amyloid-&#946; and &#945;-synuclein fibrils</article-title><source>Biochemistry</source><year>2011</year><volume>50</volume><fpage>10624</fpage><lpage>10636</lpage><pub-id pub-id-type="doi">10.1021/bi2012383</pub-id><pub-id pub-id-type="pmid">22054421</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Grelle, G. et al. Black tea Theaflavins inhibit formation of toxic amyloid-&#946; and &#945;-synuclein fibrils. <italic toggle="yes">Biochemistry</italic><bold>50</bold>, 10624&#8211;10636 (2011).<pub-id pub-id-type="pmid">22054421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bi2012383</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temsamani</surname><given-names>H</given-names></name><etal/></person-group><article-title>Piceatannol and other wine stilbenes: a pool of inhibitors against &#945;-synuclein aggregation and cytotoxicity</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><fpage>367</fpage><pub-id pub-id-type="doi">10.3390/nu8060367</pub-id><pub-id pub-id-type="pmid">27314384</pub-id><pub-id pub-id-type="pmcid">PMC4924208</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Temsamani, H. et al. Piceatannol and other wine stilbenes: a pool of inhibitors against &#945;-synuclein aggregation and cytotoxicity. <italic toggle="yes">Nutrients</italic><bold>8</bold>, 367 (2016).<pub-id pub-id-type="pmid">27314384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu8060367</pub-id><pub-id pub-id-type="pmcid">PMC4924208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ehrnhoefer</surname><given-names>DE</given-names></name><etal/></person-group><article-title>EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers</article-title><source>Nat. Struct. Mol. Biol.</source><year>2008</year><volume>15</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1437</pub-id><pub-id pub-id-type="pmid">18511942</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ehrnhoefer, D. E. et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. <italic toggle="yes">Nat. Struct. Mol. Biol.</italic><bold>15</bold>, 558&#8211;566 (2008).<pub-id pub-id-type="pmid">18511942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nsmb.1437</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hornedo-Ortega</surname><given-names>R</given-names></name><etal/></person-group><article-title>Protocatechuic acid: Inhibition of fibril formation, destabilization of preformed fibrils of amyloid-&#946; and &#945;-synuclein, and neuroprotection</article-title><source>J. Agric. Food Chem.</source><year>2016</year><volume>64</volume><fpage>7722</fpage><lpage>7732</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.6b03217</pub-id><pub-id pub-id-type="pmid">27686873</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Hornedo-Ortega, R. et al. Protocatechuic acid: Inhibition of fibril formation, destabilization of preformed fibrils of amyloid-&#946; and &#945;-synuclein, and neuroprotection. <italic toggle="yes">J. Agric. Food Chem.</italic><bold>64</bold>, 7722&#8211;7732 (2016).<pub-id pub-id-type="pmid">27686873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jafc.6b03217</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palazzi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Oleuropein aglycone stabilizes the monomeric &#945;-synuclein and favours the growth of non-toxic aggregates</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>8337</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-26645-5</pub-id><pub-id pub-id-type="pmid">29844450</pub-id><pub-id pub-id-type="pmcid">PMC5974307</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Palazzi, L. et al. Oleuropein aglycone stabilizes the monomeric &#945;-synuclein and favours the growth of non-toxic aggregates. <italic toggle="yes">Sci. Rep.</italic><bold>8</bold>, 8337 (2018).<pub-id pub-id-type="pmid">29844450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-26645-5</pub-id><pub-id pub-id-type="pmcid">PMC5974307</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hornedo-Ortega</surname><given-names>R</given-names></name><name name-style="western"><surname>Cerezo</surname><given-names>AB</given-names></name><name name-style="western"><surname>Troncoso</surname><given-names>AM</given-names></name><name name-style="western"><surname>Garcia-Parrilla</surname><given-names>MC</given-names></name></person-group><article-title>Protective effects of Hydroxytyrosol against &#945;-synuclein toxicity on PC12 cells and fibril formation</article-title><source>Food Chem. Toxicol.</source><year>2018</year><volume>120</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2018.06.059</pub-id><pub-id pub-id-type="pmid">29964084</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Hornedo-Ortega, R., Cerezo, A. B., Troncoso, A. M. &amp; Garcia-Parrilla, M. C. Protective effects of Hydroxytyrosol against &#945;-synuclein toxicity on PC12 cells and fibril formation. <italic toggle="yes">Food Chem. Toxicol.</italic><bold>120</bold>, 41&#8211;49 (2018).<pub-id pub-id-type="pmid">29964084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fct.2018.06.059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charbel</surname><given-names>EHM</given-names></name><name name-style="western"><surname>Mahmoodian</surname><given-names>F</given-names></name><name name-style="western"><surname>Tomita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sidhu</surname><given-names>A</given-names></name></person-group><article-title>Dopamine differentially induces aggregation of A53T mutant and wild type a-synuclein: insights into the protein chemistry of parkinson&#8217;s disease</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2008</year><volume>365</volume><fpage>833</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.11.075</pub-id><pub-id pub-id-type="pmid">18039462</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Charbel, E. H. M., Mahmoodian, F., Tomita, Y. &amp; Sidhu, A. Dopamine differentially induces aggregation of A53T mutant and wild type a-synuclein: insights into the protein chemistry of parkinson&#8217;s disease. <italic toggle="yes">Biochem. Biophys. Res. Commun.</italic><bold>365</bold>, 833&#8211;839 (2008).<pub-id pub-id-type="pmid">18039462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2007.11.075</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ono</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M</given-names></name></person-group><article-title>Antioxidant compounds have potent anti-fibrillogenic and fibril&#8208;destabilizing effects for &#945;&#8208;synuclein fibrils in vitro</article-title><source>J. Neurochem</source><year>2006</year><volume>97</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03707.x</pub-id><pub-id pub-id-type="pmid">16524383</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Ono, K. &amp; Yamada, M. Antioxidant compounds have potent anti-fibrillogenic and fibril&#8208;destabilizing effects for &#945;&#8208;synuclein fibrils in vitro. <italic toggle="yes">J. Neurochem</italic>. <bold>97</bold>, 105&#8211;115 (2006).<pub-id pub-id-type="pmid">16524383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-4159.2006.03707.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Inhibition of &#945;-synuclein fibrillization by dopamine analogs via reaction with the amino groups of &#945;&#8208;synuclein: implication for dopaminergic neurodegeneration</article-title><source>FEBS J.</source><year>2005</year><volume>272</volume><fpage>3661</fpage><lpage>3672</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2005.04792.x</pub-id><pub-id pub-id-type="pmid">16008565</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Li, H. et al. Inhibition of &#945;-synuclein fibrillization by dopamine analogs via reaction with the amino groups of &#945;&#8208;synuclein: implication for dopaminergic neurodegeneration. <italic toggle="yes">FEBS J.</italic><bold>272</bold>, 3661&#8211;3672 (2005).<pub-id pub-id-type="pmid">16008565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-4658.2005.04792.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masuda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Small molecule inhibitors of &#945;-synuclein filament assembly</article-title><source>Biochemistry</source><year>2006</year><volume>45</volume><fpage>6085</fpage><lpage>6094</lpage><pub-id pub-id-type="doi">10.1021/bi0600749</pub-id><pub-id pub-id-type="pmid">16681381</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Masuda, M. et al. Small molecule inhibitors of &#945;-synuclein filament assembly. <italic toggle="yes">Biochemistry</italic><bold>45</bold>, 6085&#8211;6094 (2006).<pub-id pub-id-type="pmid">16681381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bi0600749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M</given-names></name><name name-style="western"><surname>Rajamani</surname><given-names>S</given-names></name><name name-style="western"><surname>Uversky</surname><given-names>VN</given-names></name><name name-style="western"><surname>Fink</surname><given-names>AL</given-names></name></person-group><article-title>Rifampicin inhibits &#945;-synuclein fibrillation and disaggregates fibrils</article-title><source>Chem. Biol.</source><year>2004</year><volume>11</volume><fpage>1513</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2004.08.025</pub-id><pub-id pub-id-type="pmid">15556002</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Li, J., Zhu, M., Rajamani, S., Uversky, V. N. &amp; Fink, A. L. Rifampicin inhibits &#945;-synuclein fibrillation and disaggregates fibrils. <italic toggle="yes">Chem. Biol.</italic><bold>11</bold>, 1513&#8211;1521 (2004).<pub-id pub-id-type="pmid">15556002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2004.08.025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahsan</surname><given-names>N</given-names></name><name name-style="western"><surname>Siddique</surname><given-names>IA</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Surolia</surname><given-names>A</given-names></name></person-group><article-title>A routinely used protein staining dye acts as an inhibitor of wild type and mutant alpha-synuclein aggregation and modulator of neurotoxicity</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>143</volume><fpage>1174</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.10.002</pub-id><pub-id pub-id-type="pmid">29150334</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Ahsan, N., Siddique, I. A., Gupta, S. &amp; Surolia, A. A routinely used protein staining dye acts as an inhibitor of wild type and mutant alpha-synuclein aggregation and modulator of neurotoxicity. <italic toggle="yes">Eur. J. Med. Chem.</italic><bold>143</bold>, 1174&#8211;1184 (2018).<pub-id pub-id-type="pmid">29150334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2017.10.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hemin as a generic and potent protein misfolding inhibitor</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2014</year><volume>454</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.10.062</pub-id><pub-id pub-id-type="pmid">25450392</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Liu, Y. et al. Hemin as a generic and potent protein misfolding inhibitor. <italic toggle="yes">Biochem. Biophys. Res. Commun.</italic><bold>454</bold>, 295&#8211;300 (2014).<pub-id pub-id-type="pmid">25450392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2014.10.062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry&#8211;mass spectrometry</article-title><source>Nat. Chem.</source><year>2015</year><volume>7</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/nchem.2129</pub-id><pub-id pub-id-type="pmid">25515893</pub-id><pub-id pub-id-type="pmcid">PMC4280571</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Young, L. M. et al. Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry&#8211;mass spectrometry. <italic toggle="yes">Nat. Chem.</italic><bold>7</bold>, 73&#8211;81 (2015).<pub-id pub-id-type="pmid">25515893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchem.2129</pub-id><pub-id pub-id-type="pmcid">PMC4280571</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrikanth Gadad</surname><given-names>B</given-names></name><name name-style="western"><surname>Subramanya</surname><given-names>K</given-names></name><name name-style="western"><surname>Pullabhatla</surname><given-names>P</given-names></name><name name-style="western"><surname>Shantharam</surname><given-names>SS</given-names></name><name name-style="western"><surname>KS</surname><given-names>R</given-names></name></person-group><article-title>Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits &#945;-synuclein oligomer formation: relevance to parkinson&#8217;s disease</article-title><source>Curr. Pharm. Des.</source><year>2012</year><volume>18</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.2174/138161212798919093</pub-id><pub-id pub-id-type="pmid">22211690</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Shrikanth Gadad, B., Subramanya, K., Pullabhatla, P., Shantharam, S. S., KS, R. &amp; I. &amp; Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits &#945;-synuclein oligomer formation: relevance to parkinson&#8217;s disease. <italic toggle="yes">Curr. Pharm. Des.</italic><bold>18</bold>, 76&#8211;84 (2012).<pub-id pub-id-type="pmid">22211690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138161212798919093</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ardah</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils</article-title><source>Neurobiol. Dis.</source><year>2015</year><volume>74</volume><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.11.007</pub-id><pub-id pub-id-type="pmid">25449909</pub-id><pub-id pub-id-type="pmcid">PMC4882765</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Ardah, M. T. et al. Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. <italic toggle="yes">Neurobiol. Dis.</italic><bold>74</bold>, 89&#8211;101 (2015).<pub-id pub-id-type="pmid">25449909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2014.11.007</pub-id><pub-id pub-id-type="pmcid">PMC4882765</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K</given-names></name></person-group><article-title>Isoliquiritigenin and liquiritin from glycyrrhiza uralensis inhibit &#945;-synuclein amyloid formation</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>86640</fpage><lpage>86649</lpage><pub-id pub-id-type="doi">10.1039/C6RA17770K</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Liao, M., Zhao, Y., Huang, L., Cheng, B. &amp; Huang, K. Isoliquiritigenin and liquiritin from glycyrrhiza uralensis inhibit &#945;-synuclein amyloid formation. <italic toggle="yes">RSC Adv.</italic><bold>6</bold>, 86640&#8211;86649 (2016).</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva</surname><given-names>FL</given-names></name><etal/></person-group><article-title>Vitamins K interact with N-terminus &#945;-synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between Quinones and &#945;-synuclein</article-title><source>Neurochem Int.</source><year>2013</year><volume>62</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2012.10.001</pub-id><pub-id pub-id-type="pmid">23064431</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">da Silva, F. L. et al. Vitamins K interact with N-terminus &#945;-synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between Quinones and &#945;-synuclein. <italic toggle="yes">Neurochem Int.</italic><bold>62</bold>, 103&#8211;112 (2013).<pub-id pub-id-type="pmid">23064431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuint.2012.10.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inhibition effects of Tanshinone on the aggregation of &#945;-synuclein</article-title><source>Food Funct.</source><year>2016</year><volume>7</volume><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1039/C5FO00664C</pub-id><pub-id pub-id-type="pmid">26456030</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Ji, K. et al. Inhibition effects of Tanshinone on the aggregation of &#945;-synuclein. <italic toggle="yes">Food Funct.</italic><bold>7</bold>, 409&#8211;416 (2016).<pub-id pub-id-type="pmid">26456030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c5fo00664c</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrasidlo</surname><given-names>W</given-names></name><etal/></person-group><article-title>A de Novo compound targeting &#945;-synuclein improves deficits in models of parkinson&#8217;s disease</article-title><source>Brain</source><year>2016</year><volume>139</volume><fpage>3217</fpage><lpage>3236</lpage><pub-id pub-id-type="doi">10.1093/brain/aww238</pub-id><pub-id pub-id-type="pmid">27679481</pub-id><pub-id pub-id-type="pmcid">PMC5840882</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Wrasidlo, W. et al. A de Novo compound targeting &#945;-synuclein improves deficits in models of parkinson&#8217;s disease. <italic toggle="yes">Brain</italic><bold>139</bold>, 3217&#8211;3236 (2016).<pub-id pub-id-type="pmid">27679481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww238</pub-id><pub-id pub-id-type="pmcid">PMC5840882</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>DL</given-names></name><etal/></person-group><article-title>The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of parkinson&#8217;s disease</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>16165</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-34490-9</pub-id><pub-id pub-id-type="pmid">30385782</pub-id><pub-id pub-id-type="pmcid">PMC6212487</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Price, D. L. et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of parkinson&#8217;s disease. <italic toggle="yes">Sci. Rep.</italic><bold>8</bold>, 16165 (2018).<pub-id pub-id-type="pmid">30385782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-34490-9</pub-id><pub-id pub-id-type="pmcid">PMC6212487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herva</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Anti-amyloid compounds inhibit &#945;-synuclein aggregation induced by protein misfolding Cyclic amplification (PMCA)</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>11897</fpage><lpage>11905</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.542340</pub-id><pub-id pub-id-type="pmid">24584936</pub-id><pub-id pub-id-type="pmcid">PMC4002097</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Herva, M. E. et al. Anti-amyloid compounds inhibit &#945;-synuclein aggregation induced by protein misfolding Cyclic amplification (PMCA). <italic toggle="yes">J. Biol. Chem.</italic><bold>289</bold>, 11897&#8211;11905 (2014).<pub-id pub-id-type="pmid">24584936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M113.542340</pub-id><pub-id pub-id-type="pmcid">PMC4002097</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhavale</surname><given-names>DD</given-names></name><etal/></person-group><article-title>A sensitive assay reveals structural requirements for &#945;-synuclein fibril growth</article-title><source>J. Biol. Chem.</source><year>2017</year><volume>292</volume><fpage>9034</fpage><lpage>9050</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.767053</pub-id><pub-id pub-id-type="pmid">28373279</pub-id><pub-id pub-id-type="pmcid">PMC5454090</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Dhavale, D. D. et al. A sensitive assay reveals structural requirements for &#945;-synuclein fibril growth. <italic toggle="yes">J. Biol. Chem.</italic><bold>292</bold>, 9034&#8211;9050 (2017).<pub-id pub-id-type="pmid">28373279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M116.767053</pub-id><pub-id pub-id-type="pmcid">PMC5454090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Dhavale, D. D. et al. Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue. <italic toggle="yes">bioRxiv</italic> 2023.01.09.523303 (2023). 10.1101/2023.01.09.523303<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-46832-5</pub-id><pub-id pub-id-type="pmcid">PMC10980826</pub-id><pub-id pub-id-type="pmid">38553463</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedov</surname><given-names>I</given-names></name><name name-style="western"><surname>Khaibrakhmanova</surname><given-names>D</given-names></name></person-group><article-title>Molecular mechanisms of Inhibition of protein amyloid fibril formation: evidence and perspectives based on kinetic models</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><fpage>13428</fpage><pub-id pub-id-type="doi">10.3390/ijms232113428</pub-id><pub-id pub-id-type="pmid">36362217</pub-id><pub-id pub-id-type="pmcid">PMC9657184</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Sedov, I. &amp; Khaibrakhmanova, D. Molecular mechanisms of Inhibition of protein amyloid fibril formation: evidence and perspectives based on kinetic models. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>23</bold>, 13428 (2022).<pub-id pub-id-type="pmid">36362217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232113428</pub-id><pub-id pub-id-type="pmcid">PMC9657184</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afitska</surname><given-names>K</given-names></name><name name-style="western"><surname>Priss</surname><given-names>A</given-names></name><name name-style="western"><surname>Yushchenko</surname><given-names>DA</given-names></name><name name-style="western"><surname>Shvadchak</surname><given-names>VV</given-names></name></person-group><article-title>Structural optimization of inhibitors of &#945;-synuclein fibril growth: affinity to the fibril end as a crucial factor</article-title><source>J. Mol. Biol.</source><year>2020</year><volume>432</volume><fpage>967</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.11.019</pub-id><pub-id pub-id-type="pmid">31809698</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Afitska, K., Priss, A., Yushchenko, D. A. &amp; Shvadchak, V. V. Structural optimization of inhibitors of &#945;-synuclein fibril growth: affinity to the fibril end as a crucial factor. <italic toggle="yes">J. Mol. Biol.</italic><bold>432</bold>, 967&#8211;977 (2020).<pub-id pub-id-type="pmid">31809698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmb.2019.11.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassen</surname><given-names>LB</given-names></name><etal/></person-group><article-title>ELISA method to detect &#945;-synuclein oligomers in cell and animal models</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><fpage>e0196056</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0196056</pub-id><pub-id pub-id-type="pmid">29698510</pub-id><pub-id pub-id-type="pmcid">PMC5919555</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Lassen, L. B. et al. ELISA method to detect &#945;-synuclein oligomers in cell and animal models. <italic toggle="yes">PLoS One</italic>. <bold>13</bold>, e0196056 (2018).<pub-id pub-id-type="pmid">29698510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0196056</pub-id><pub-id pub-id-type="pmcid">PMC5919555</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Structures of &#945;-synuclein filaments from human brains with lewy pathology</article-title><source>Nature</source><year>2022</year><volume>610</volume><fpage>791</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05319-3</pub-id><pub-id pub-id-type="pmid">36108674</pub-id><pub-id pub-id-type="pmcid">PMC7613749</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Yang, Y. et al. Structures of &#945;-synuclein filaments from human brains with lewy pathology. <italic toggle="yes">Nature</italic><bold>610</bold>, 791&#8211;795 (2022).<pub-id pub-id-type="pmid">36108674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05319-3</pub-id><pub-id pub-id-type="pmcid">PMC7613749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhavale</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Structure of alpha-synuclein fibrils derived from human lewy body dementia tissue</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>2750</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-46832-5</pub-id><pub-id pub-id-type="pmid">38553463</pub-id><pub-id pub-id-type="pmcid">PMC10980826</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Dhavale, D. D. et al. Structure of alpha-synuclein fibrils derived from human lewy body dementia tissue. <italic toggle="yes">Nat. Commun.</italic><bold>15</bold>, 2750 (2024).<pub-id pub-id-type="pmid">38553463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-46832-5</pub-id><pub-id pub-id-type="pmcid">PMC10980826</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eberhardt</surname><given-names>J</given-names></name><name name-style="western"><surname>Santos-Martins</surname><given-names>D</given-names></name><name name-style="western"><surname>Tillack</surname><given-names>AF</given-names></name><name name-style="western"><surname>Forli</surname><given-names>S</given-names></name></person-group><article-title>AutoDock Vina 1.2. 0: new Docking methods, expanded force field, and python bindings</article-title><source>J. Chem. Inf. Model.</source><year>2021</year><volume>61</volume><fpage>3891</fpage><lpage>3898</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.1c00203</pub-id><pub-id pub-id-type="pmid">34278794</pub-id><pub-id pub-id-type="pmcid">PMC10683950</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Eberhardt, J., Santos-Martins, D., Tillack, A. F. &amp; Forli, S. AutoDock Vina 1.2. 0: new Docking methods, expanded force field, and python bindings. <italic toggle="yes">J. Chem. Inf. Model.</italic><bold>61</bold>, 3891&#8211;3898 (2021).<pub-id pub-id-type="pmid">34278794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.1c00203</pub-id><pub-id pub-id-type="pmcid">PMC10683950</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bitan</surname><given-names>G</given-names></name></person-group><article-title>The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question&#8212;are polyphenols a viable therapeutic option against proteinopathies?</article-title><source>Ann Transl Med</source><year>2020</year><volume>8</volume><fpage>719</fpage><pub-id pub-id-type="doi">10.21037/atm.2020.01.117</pub-id><pub-id pub-id-type="pmid">32617339</pub-id><pub-id pub-id-type="pmcid">PMC7327354</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Bitan, G. The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question&#8212;are polyphenols a viable therapeutic option against proteinopathies? <italic toggle="yes">Ann Transl Med</italic><bold>8</bold>, 10.21037/atm.2020.01.117719. (2020).<pub-id pub-id-type="pmid">32617339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm.2020.01.117</pub-id><pub-id pub-id-type="pmcid">PMC7327354</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Safety and efficacy of Epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Neurol.</source><year>2019</year><volume>18</volume><fpage>724</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30141-3</pub-id><pub-id pub-id-type="pmid">31278067</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Levin, J. et al. Safety and efficacy of Epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <italic toggle="yes">Lancet Neurol.</italic><bold>18</bold>, 724&#8211;735 (2019).<pub-id pub-id-type="pmid">31278067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(19)30141-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smit</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Phase 1/1b studies of UCB0599, an oral inhibitor of &#945;-Synuclein misfolding, including a randomized study in parkinson&#8217;s disease</article-title><source>Mov. Disord</source><year>2022</year><volume>37</volume><fpage>2045</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1002/mds.29170</pub-id><pub-id pub-id-type="pmid">35959805</pub-id><pub-id pub-id-type="pmcid">PMC9804489</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Smit, J. W. et al. Phase 1/1b studies of UCB0599, an oral inhibitor of &#945;-Synuclein misfolding, including a randomized study in parkinson&#8217;s disease. <italic toggle="yes">Mov. Disord</italic>. <bold>37</bold>, 2045&#8211;2056 (2022).<pub-id pub-id-type="pmid">35959805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29170</pub-id><pub-id pub-id-type="pmcid">PMC9804489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inhibition of &#945;-synuclein aggregation by MT101-5 is neuroprotective in mouse models of parkinson&#8217;s disease</article-title><source>Biomed. Pharmacother</source><year>2022</year><volume>154</volume><fpage>113637</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113637</pub-id><pub-id pub-id-type="pmid">36058149</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Kim, S. et al. Inhibition of &#945;-synuclein aggregation by MT101-5 is neuroprotective in mouse models of parkinson&#8217;s disease. <italic toggle="yes">Biomed. Pharmacother</italic>. <bold>154</bold>, 113637 (2022).<pub-id pub-id-type="pmid">36058149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2022.113637</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dervi&#351;o&#287;lu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Anle138b interaction in &#945;-synuclein aggregates by dynamic nuclear polarization NMR</article-title><source>Methods</source><year>2023</year><volume>214</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2023.04.002</pub-id><pub-id pub-id-type="pmid">37037308</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Dervi&#351;o&#287;lu, R. et al. Anle138b interaction in &#945;-synuclein aggregates by dynamic nuclear polarization NMR. <italic toggle="yes">Methods</italic><bold>214</bold>, 18&#8211;27 (2023).<pub-id pub-id-type="pmid">37037308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymeth.2023.04.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>J</given-names></name><etal/></person-group><article-title>Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and parkinson&#8217;s disease</article-title><source>Acta Neuropathol.</source><year>2013</year><volume>125</volume><fpage>795</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1114-9</pub-id><pub-id pub-id-type="pmid">23604588</pub-id><pub-id pub-id-type="pmcid">PMC3661926</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wagner, J. et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and parkinson&#8217;s disease. <italic toggle="yes">Acta Neuropathol.</italic><bold>125</bold>, 795&#8211;813 (2013).<pub-id pub-id-type="pmid">23604588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-013-1114-9</pub-id><pub-id pub-id-type="pmcid">PMC3661926</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acharya</surname><given-names>S</given-names></name><etal/></person-group><article-title>Molecular basis for preventing &#945;-synuclein aggregation by a molecular tweezer</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>10727</fpage><lpage>10737</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.524520</pub-id><pub-id pub-id-type="pmid">24567327</pub-id><pub-id pub-id-type="pmcid">PMC4036189</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Acharya, S. et al. Molecular basis for preventing &#945;-synuclein aggregation by a molecular tweezer. <italic toggle="yes">J. Biol. Chem.</italic><bold>289</bold>, 10727&#8211;10737 (2014).<pub-id pub-id-type="pmid">24567327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M113.524520</pub-id><pub-id pub-id-type="pmcid">PMC4036189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins</article-title><source>J. Am. Chem. Soc.</source><year>2011</year><volume>133</volume><fpage>16958</fpage><lpage>16969</lpage><pub-id pub-id-type="doi">10.1021/ja206279b</pub-id><pub-id pub-id-type="pmid">21916458</pub-id><pub-id pub-id-type="pmcid">PMC3210512</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Sinha, S. et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. <italic toggle="yes">J. Am. Chem. Soc.</italic><bold>133</bold>, 16958&#8211;16969 (2011).<pub-id pub-id-type="pmid">21916458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja206279b</pub-id><pub-id pub-id-type="pmcid">PMC3210512</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prabhudesai</surname><given-names>S</given-names></name><etal/></person-group><article-title>A novel molecular tweezer inhibitor of &#945;-synuclein neurotoxicity in vitro and in vivo</article-title><source>Neurotherapeutics</source><year>2012</year><volume>9</volume><fpage>464</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1007/s13311-012-0105-1</pub-id><pub-id pub-id-type="pmid">22373667</pub-id><pub-id pub-id-type="pmcid">PMC3337029</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Prabhudesai, S. et al. A novel molecular tweezer inhibitor of &#945;-synuclein neurotoxicity in vitro and in vivo. <italic toggle="yes">Neurotherapeutics</italic><bold>9</bold>, 464&#8211;476 (2012).<pub-id pub-id-type="pmid">22373667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13311-012-0105-1</pub-id><pub-id pub-id-type="pmcid">PMC3337029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrera-Vaquero</surname><given-names>M</given-names></name><etal/></person-group><article-title>The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent &#945;-synuclein in experimental multiple system atrophy</article-title><source>Biochim. Biophys. Acta (BBA)-Molecular Basis Dis.</source><year>2019</year><volume>1865</volume><fpage>165513</fpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2019.07.007</pub-id><pub-id pub-id-type="pmcid">PMC8425273</pub-id><pub-id pub-id-type="pmid">31319154</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Herrera-Vaquero, M. et al. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent &#945;-synuclein in experimental multiple system atrophy. <italic toggle="yes">Biochim. Biophys. Acta (BBA)-Molecular Basis Dis.</italic><bold>1865</bold>, 165513 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2019.07.007</pub-id><pub-id pub-id-type="pmcid">PMC8425273</pub-id><pub-id pub-id-type="pmid">31319154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Quantifying regional &#945;-synuclein, amyloid &#946;, and Tau accumulation in lewy body dementia</article-title><source>Ann. Clin. Transl Neurol.</source><year>2022</year><volume>9</volume><fpage>106</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1002/acn3.51482</pub-id><pub-id pub-id-type="pmid">35060360</pub-id><pub-id pub-id-type="pmcid">PMC8862415</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Miller, R. L. et al. Quantifying regional &#945;-synuclein, amyloid &#946;, and Tau accumulation in lewy body dementia. <italic toggle="yes">Ann. Clin. Transl Neurol.</italic><bold>9</bold>, 106&#8211;121 (2022).<pub-id pub-id-type="pmid">35060360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.51482</pub-id><pub-id pub-id-type="pmcid">PMC8862415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>Scheres</surname><given-names>SH</given-names></name></person-group><article-title>W. Helical reconstruction in RELION</article-title><source>J. Struct. Biol.</source><year>2017</year><volume>198</volume><fpage>163</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2017.02.003</pub-id><pub-id pub-id-type="pmid">28193500</pub-id><pub-id pub-id-type="pmcid">PMC5479445</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">He, S. &amp; Scheres, S. H. W. Helical reconstruction in RELION. <italic toggle="yes">J. Struct. Biol.</italic><bold>198</bold>, 163&#8211;176 (2017).<pub-id pub-id-type="pmid">28193500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsb.2017.02.003</pub-id><pub-id pub-id-type="pmcid">PMC5479445</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>